牛牛AI助理已提取核心訊息
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 2,465 shares of common stock on February 28, 2024. The transaction was executed at a price of $10.60 per share, resulting in a total market value of $26,129. Following the sale, Watanabe directly holds 889,436 shares of the company. Additionally, Watanabe has indirect ownership of 231,140 shares through trusts and an LLC. The sale took place in an open market or private sale, as per the transaction code description.
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 2,465 shares of common stock on February 28, 2024. The transaction was executed at a price of $10.60 per share, resulting in a total market value of $26,129. Following the sale, Watanabe directly holds 889,436 shares of the company. Additionally, Watanabe has indirect ownership of 231,140 shares through trusts and an LLC. The sale took place in an open market or private sale, as per the transaction code description.
與Arcutis Biotherapeutics有聯繫的渡邊託德·富蘭克林於2024年2月28日完成了2465股普通股的出售。該交易以每股10.60美元的價格執行，總市值爲26,129美元。出售後，渡邊直接持有該公司的889,436股股份。此外，渡邊通過信託和有限責任公司間接擁有231,140股股份。根據交易代碼描述，此次出售是在公開市場或私人銷售中進行的。
與Arcutis Biotherapeutics有聯繫的渡邊託德·富蘭克林於2024年2月28日完成了2465股普通股的出售。該交易以每股10.60美元的價格執行，總市值爲26,129美元。出售後，渡邊直接持有該公司的889,436股股份。此外，渡邊通過信託和有限責任公司間接擁有231,140股股份。根據交易代碼描述，此次出售是在公開市場或私人銷售中進行的。
有用
沒用